President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments, Delivering New Hope to Veterans

The White House announcement centers on an executive order meant to accelerate mental health treatments for people with serious mental illness, with a stated focus on veterans. The order directs the FDA to use National Priority Vouchers for psychedelic drugs that have Breakthrough Therapy designations and qualify under the program criteria. It also directs the FDA and DEA to create a pathway for eligible patients to access eligible investigational psychedelic drugs under review, including ibogaine compounds, subject to safety requirements connected to the Right to Try framework. The order further assigns $50 million through ARPA-H to match state investment for research into psychedelic programs for serious mental illness, and calls for collaboration with the Department of Veterans Affairs and the private sector to expand clinical trial participation and evidence generation. It also instructs the Attorney General to initiate relevant product reviews after successful Phase 3 trials to enable rescheduling as soon as possible after FDA approval.